BLOCKERS OF LIGHT, LTalpha1beta2 AND LTalpha2beta1 OR ITS RECEPTOR LTbetaR FOR THE PREVENTION AND TREATMENT OF CHRONIC HEPATITIS AND OTHER LIVER DISEASES
AssigneeUniversitaet Zuerich
InventorsMathias Heikenwaelder, Adriano Aguzzi
Life of this patent
Estimating the term…
Abstract
The present invention relates to a method of preventing and treating chronic hepatitis and other liver diseases comprising administering a blocker of Light, LTα1β2, LTα2β1 or LTβR, and the use of such blockers in said prevention and treatment and in the manufacture of medicaments for preventing and treating chronic hepatitis and other liver diseases.
Claims20
A blocker of the cytokines Light, LTα1β2 and LTα2β1 or its receptor LTβR for use in the prevention and treatment of chronic hepatitis and other liver diseases.
A method of claim 15, wherein the liver diseases are hepatocellular carcinoma (HCC), liver fibrosis, liver cirrhosis, hemochromatosis, non-alcoholic steatohepatitis (NASH), chemotherapy associated hepatits (CASH), Wilson's disease, hepatosteatosis and bile duct diseases.
A method of claim 15, wherein hepatitis B and C are treated and prevented.
A method of claim 15, wherein the liver disease is hepatocellular carcinoma.
A method of screening for a compound effective in the prevention and treatment of chronic hepatitis and other liver diseases, comprising contacting a candidate compound with Light, LTβR, LTα1β2 or LTα2β1 and choosing candidate compounds which selectively reduce activity of Light, LTβR, LTα1β2 or LTα2β1.
A method of preventing and treating chronic hepatitis and other liver diseases, comprising administering blockers of Light, LTα1β2 and LTα2β1 or its receptor LTβR in a quantity effective against chronic hepatitis and other liver diseases to a mammal in need thereof.
Dependencies are inferred from the claim text.